Fizazi, Karim

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

Smith, M. R., Coleman, R. E., Klotz, L., Pittman, K., Milecki, P., Ng, S., Chi, K. N., Balakumaran, A., Wei, R., Wang, H., et al. (2015) · Annals of Oncology

Bone health and treatmentsProstate Cancer Treatment and Research

Cited by 145

Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer

Fizazi, K., Massard, C., Smith, M., Rader, M., Brown, J., Milecki, P., Shore, N., Oudard, S., Karsh, L., Carducci, M., et al. (2015) · European Urology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 142

Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021

Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., et al. (2022) · European Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 130

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 125

Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents

Fizazi, K., & Gillessen, S. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 119

Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial)

Kuo, P. H., Morris, M. J., Hesterman, J., Kendi, A. T., Rahbar, K., Wei, X. X., Fang, B., Adra, N., Garje, R., Michalski, J. M., et al. (2024) · Radiology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 119

Metastatic prostate cancer and the bone: significance and therapeutic options

Gartrell, B. A., Coleman, R., Efstathiou, E., Fizazi, K., Logothetis, C. J., Smith, M. R., Sonpavde, G., Sartor, O., & Saad, F. (2015) · European Urology

Bone health and treatmentsProstate Cancer Treatment and Research

Cited by 101

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

Terrisse, S., Goubet, A.-G., Ueda, K., Thomas, A. M., Quiniou, V., Thelemaque, C., Dunsmore, G., Clave, E., Gamat-Huber, M., Yonekura, S., et al. (2022) · Journal for ImmunoTherapy of Cancer

Prostate Cancer Treatment and ResearchGut microbiota and health

Cited by 80

Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial

Cella, D., Ivanescu, C., Holmstrom, S., Bui, C. N., Spalding, J., & Fizazi, K. (2015) · Annals of Oncology

Prostate Cancer Treatment and ResearchCancer survivorship and care

Cited by 79

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

Armstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., et al. (2018) · Annals of Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 71

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Sartor, O., Castellano Gauna, D. E., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N. N., Crosby, M., Piulats Rodriguez, J. M., Flechon, A., Wei, X. X., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 71

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial

Lavaud, P., Gravis, G., Foulon, S., Joly, F., Oudard, S., Priou, F., Latorzeff, I., Mourey, L., Soulié, M., Delva, R., et al. (2018) · European Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 63

Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302

Saad, F., Shore, N., Van Poppel, H., Rathkopf, D. E., Smith, M. R., de Bono, J. S., Logothetis, C. J., de Souza, P., Fizazi, K., Mulders, P. F. A., et al. (2015) · European Urology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 63

Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer

Chi, K. N., Armstrong, A. J., Krause, B. J., Herrmann, K., Rahbar, K., de Bono, J. S., Adra, N., Garje, R., Michalski, J. M., Kempel, M. M., et al. (2024) · European Urology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 37

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Halabi, S., Yang, Q., Roy, A., Luo, B., Araujo, J. C., Logothetis, C., Sternberg, C. N., Armstrong, A. J., Carducci, M. A., Chi, K. N., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 30

Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: a meta-analysis of AFFIRM, PREVAIL and PROSPER

Joshua, A. M., Armstrong, A., Crumbaker, M., Scher, H. I., de Bono, J., Tombal, B., Hussain, M., Sternberg, C. N., Gillessen, S., Carles, J., et al. (2022) · European Journal of Cancer

Prostate Cancer Treatment and ResearchCancer, Lipids, and Metabolism

Cited by 28

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

Fizazi, K., Azad, A., Matsubara, N., Carles, J., Fay, A. P., De Giorgi, U., Joung, J. Y., Fong, P. C. C., Voog, E., Jones, R. J., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 17

Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.

Krause, B. J., Chi, K. N., Sartor, A. O., Fizazi, K., Morris, M. J., De Bono, J. S., Tagawa, S. T., Herrmann, K., Kurth, J., Eiber, M., et al. (2023) · Journal of Clinical Oncology

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 11

A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption

Suarez, T., Fizazi, K., Rahim, Y., Wilson, J., Fan, M., Jun, S., & Lipton, A. (2006) · Journal of Clinical Oncology

Bone health and treatmentsBone health and osteoporosis research

Cited by 11

1842TiP Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)

de Bono, J. S., Sandhu, S. K., Fizazi, K., Sun, J., Ward, A., & Antonarakis, E. S. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 6